1. Bulatović, M., Heijstek, M. W., Van Dijkhuizen, E. P., Wulffraat, N. M., Pluijm, S. M., & de Jonge, R. (2012). Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Annals of the rheumatic diseases, 71(9), 1484-1489.

2. Chen, J., Chen, L., Mao, N., & Liu, Y. (2012). Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatology international, 32(10), 3127-3130.

3. Drozdzik, M., Rudas, T., Pawlik, A., Kurzawski, M., Czerny, B., Gornik, W., & Herczynska, M. (2006). The effect of 3435C> T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. European journal of clinical pharmacology, 62(11), 933-937

4. Grabar, P. B., Logar, D., Lestan, B., & Dolžan, V. (2008). Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. European journal of clinical pharmacology, 64(11), 1057-1068

5. Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018). Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone research, 6.

6. Muralidharan, N., Antony, P. T., Jain, V. K., Mariaselvam, C. M., & Negi, V. S. (2015). Multidrug resistance 1 (MDR1) 3435C> T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. European journal of clinical pharmacology, 71(8), 959-965.

7. Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I., & Gawronska-Szklarz, B. (2004). The MDR1 3435 polymorphism in patients with rheumatoid arthritis. International journal of clinical pharmacology and therapeutics, 42(9), 496-503.

8. Sharma, S., Das, M., Kumar, A., Marwaha, V., Shankar, S., Aneja, R., ... & Kumar, U. (2008). Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenetics and genomics, 18(12), 1041-1049.

9. Samara, S. A., Irshaid, Y. M., & Mustafa, K. N. (2014). Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. International journal of clinical pharmacology and therapeutics, 52(9), 746-755.

10. Takatori, R., Takahashi, K. A., Tokunaga, D., Hojo, T., Fujioka, M., Asano, T., ... & Tanaka, T. (2006). ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol, 24(5), 546-54.